China-based biotech firm Antengene (HKG: 6996) announced the opening of its new office in Melbourne, Australia. This strategic move is aimed at supporting the company’s expansion in the Asia Pacific region, with the office covering functions including commercial operations, finance, medical affairs, and clinical and business development.
Clinical Trials and Regulatory Milestones
Antengene has several clinical trials currently underway in Australia. In March 2022, the company received approval for its lead candidate, Xpovio (selinexor), to be assessed in treating multiple myeloma (MM). In September 2022, Xpovio was added to the Pharmaceutical Benefits Scheme for patients with relapsed/refractory MM, further solidifying its position in the Australian market.
Expanding Pipeline in Australia
Antengene continues to expand its clinical footprint in Australia with four additional trials currently underway. These include studies for the ATR inhibitor ATG-018, the PD-L1/4-1BB bispecific antibody ATG-101, the small-molecule CD37 inhibitor ATG-037, and the ERK1/2 inhibitor ATG-017. These trials highlight Antengene’s commitment to advancing innovative therapies in the region.-Fineline Info & Tech
